Not all clients with CLL require therapy. Irrespective of all latest advances, the iwCLL however endorses watchful observation for patients with asymptomatic sickness.86 This advice is predicated on no less than two randomized trials comparing observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,104